{"id":"NCT03927157","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma","officialTitle":"A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults With Severe Uncontrolled Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-14","primaryCompletion":"2024-05-24","completion":"2024-08-13","firstPosted":"2019-04-25","resultsPosted":"2025-07-01","lastUpdate":"2025-07-01"},"enrollment":405,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Experimental: Tezepelumab","otherNames":["Tezepelumab"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tezepelumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma","primaryOutcome":{"measure":"Annual Asthma Exacerbation Rate (AERR)","timeFrame":"Randomization to Week 52","effectByArm":[{"arm":"Tezepelumab 210mg Q4W","deltaMin":0.42,"sd":null},{"arm":"Placebo","deltaMin":1.63,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":72,"countries":["China","Philippines","South Korea"]},"refs":{"pmids":["40782846"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00021&amp;attachmentIdentifier=3f72a345-e246-4de4-8c5d-b0cf83127dc0&amp;fileName=D5180C00021-Primary_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00021&amp;attachmentIdentifier=2fd5959d-d1d1-4532-af2e-f258447dccb3&amp;fileName=D5180C00021-Final_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00021&amp;attachmentIdentifier=bdcb0f1d-99a8-47d7-8cca-967c2e36c7c1&amp;fileName=D5180C00021_SAP_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00021&amp;attachmentIdentifier=3ae5f974-d4c4-4d0c-949b-b0add12d16bb&amp;fileName=D5180C00021_CSP_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":201},"commonTop":["Upper respiratory tract infection","Covid-19","Suspected covid-19","Nasopharyngitis","Urinary tract infection"]}}